• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 141

Featured

Featured posts
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES...

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

PT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring...

Delix Therapeutics Expands World-Class Team with First Head of R&D

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

1...140141142...301Page 141 of 301

EDITOR PICKS

Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of...

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots...

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©